Advisors

Scientific Advisors

Dr. Allan Young

Dr. Young is the Chair of Mood Disorders in the Institute of Psychiatry, Psychology and Neuroscience, and also currently serves as the Vice-Dean and Head of School of Academic Psychiatry, at King’s College London, UK. Dr. Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. Dr. Young has held academic appointments at Oxford University; Newcastle University (latterly holding the Chair of General Psychiatry at Newcastle), University of British Columbia in Vancouver, Canada, where he held the Leading Edge Endowment Fund Endowed Chair in Research in the Department of Psychiatry and was also the Director of the Institute of Mental Health and Imperial College London, where he held the Chair of Psychiatry and was Director of the Centre for Mental Health Dr Young has has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, the Canadian Institutes for Heath Research (CIHR), the National Institutes of Health (USA), and numerous other funding agencies. Dr. Young has published over 600 peer-reviewed publications and several books about psychopharmacology and affective disorders. Dr. Young was recently ranked as one of the world’s leading scientific minds in the field of psychiatry and psychology, according to the Thomson Reuters Highly Cited Researchers list. In all of science, a total of just over 3,000 researchers worldwide earned this distinction, and the academics listed rank among the top one percent most cited for their subject field and year of publication, a mark of exceptional impact.

Dr. Trisha Suppes

Dr. Suppes has an extensive background in psychiatry and recognized expert on mood disorders, particularly major depressive disorder and bipolar disorder.  Dr. Suppes areas of specialization include long-term treatment strategies for bipolar disorder, identification and treatment of bipolar II disorder, the use of complementary medicine for bipolar disorder, and has recently launched a new initiative to explore use of psychedelics for psychiatric disorders. Dr. Suppes is a Professor of Psychiatry and Behavioral Science at Stanford University, and a member of Bio-X, Stanford’s interdisciplinary biosciences institute. Dr. Suppes was the Chair of the U.S. Department of Defense, Veteran Affairs guidelines for bipolar disorder, and the Bipolar module of the Texas Medication Algorithm Project. In addition, Dr. Suppes is also Director of the Exploratory Therapeutics Laboratory and the founder of the Bipolar and Depression Research Program at the VA Palo Alto Health Care System. Dr. Suppes has over 250 publications and received numerous awards and recognition for contributions to her field. Ranked one of the leading scientific minds in the field of psychiatry and psychology, Thomson Reuters Highly Cited Researchers.

Headshot photograph of Trisha Suppes

Dr. Pierre Chue

Dr. Chue has extensive experience in clinical psychopharmacology. Dr. Chue’s experience includes acting as the Director of the Clinical Trials and Research Program, Alberta Health Services, and has been involved in over 50 national and international clinical trials in areas including depression, anxiety disorders and addiction. Dr. Chue is a researcher with the Integrative Health Institute, Centre of Excellence for Real World Clinical Outcomes and Campus Alberta Neuroscience (University of Alberta). Dr. Chue completed his medical degree (MBBCh) and psychiatric specialization (MRCPsych) in the UK before moving to Canada in 1991 where he subsequently obtained Canadian medical (LMCC) and specialist qualifications (FRCPC) as well as American Boards Certification in Psychiatry and Neurology (DABPN) and an MSc in Psychiatry at the University of Alberta. He was elected a Fellow of the Royal College of Psychiatrists (FRCPsych) in the UK in 2004.

Headshot photograph of Pierre Chue

Digital Health Advisors

Dr. Walter Greenleaf

Dr. Greenleaf is a behavioral neuroscientist and a medical technology developer working at Stanford University. With over three decades of research and development experience in the field of digital medicine and medical virtual reality technology, he is considered the leading authority in the field. Dr. Greenleaf has designed and developed numerous clinical systems over the last thirty-five years, including products in the fields of: surgical simulation, 3D medical visualization, telerehabilitation, clinical informatics, clinical decision support, point-of-care clinical data collection, ergonomic evaluation technology, automatic sleep-staging systems, psychophysiological assessment, and simulation-assisted rehabilitation technologies, as well as products for behavioral medicine. Dr. Greenleaf is currently a Distinguished Visiting Scholar at Stanford University’s MediaX Program, a Visiting Scholar at Stanford University’s Virtual Human Interaction Lab, and the Director of Technology Strategy at the University of Colorado National Mental Health Innovation Center. Dr. Greenleaf is a member of the Board of Directors for Brainstorm: The Stanford Laboratory for Brain Health Innovation and Entrepreneurship and for Sine Wave, the developer of Sine Space, a multi-user online Unity 3D-based virtual world platform, and Cognitive Leap. In addition to his research at Stanford University, Dr. Greeleaf is Senior Vice President of Strategic & Corporate Affairs to MindMaze, a global leader in brain technology, and Chief Science Advisor to Pear Therapeutics, a biotech company that develops digital therapeutics to treat disease and enhance the efficacy of pharmaceuticals. Dr. Greenleaf is a virtual reality technology and neuroscience advisor to several early-stage medical product companies, including MindStrong Health, Ellipsis Health, Limbix, Tripp, eQuility, Altoida, MyndVR, OramaVR, and BehaVR. Dr. Greenleaf earned a Doctorate in Neuro and Bio-Behavioral Sciences from the Stanford University School of Medicine, where he was awarded an NIMH Graduate Fellowship.

Headshot photograph of Walter Greenleaf

Beth Rogozinski

Ms. Beth Rogozinski is a serial entrepreneur, technology innovator, and business strategist with a background in digital medicine and medical devices. Ms. Rogozinski has worked in information technology hardware, software, and services with leading technology companies, including Silicon Graphics, Macromedia, and the digital agency Circle. Ms. Rogozinski has also founded digital gaming and application development companies including Signal 2 Productions, Match Factor and D2S Games. Ms. Rogozinski has produced and published over a dozen software applications focused on health and wellness. As Chief Product Officer at Pear Therapeutics Inc. (“Pear”), Ms. Rogozinski led the development of Pear’s first clinical products and submission of the De Novo 510k to the U.S. Food and Drug Administration (the “FDA”). Pear’s ReSET™ was cleared by the FDA in 2017 as the first ever prescription digital therapeutic. Ms. Rogozinski is a director and advisor to a number of high growth start-up companies and accelerators, and has consulted with numerous health and innovation centers, such as Stanford University, UnitedHealth Group, and the National Mental Health Innovation Center. Ms. Rogozinski is currently the Chief Executive Officer of Oncoustics, an innovative artificial intelligence solutions company that is creating low cost, non-invasive surveillance, diagnostics, and treatment monitoring for diseases with high unmet clinical needs.

Headshot photograph of Beth Rogozinski

Paula Kranz

Ms. Kranz has extensive experience in disruptive interventions and technologies through a 20-year career in U.S. Military Intelligence with Special Operations Forces and the Federal Bureau of Investigation (FBI). Ms. Kranz is the Founder and Chief Executive Officer of Medi-XR, a digital health therapeutics consulting firm based in North Carolina, and currently serves as an embedded executive in support of the Novant Health Chief Transformation and Digital Office’s Innovation and Artificial Intelligence Institute where Ms. Kranz leads innovation efforts in the digital health transformation space. Ms. Kranz previously served as Deputy Director of the Tufts University Counter Terrorism Center, a former research associate at Harvard University, and was an instructor at the U.S. Military Academy. Ms. Kranz holds an MBA from Oxford University, with a focus on disruptive healthcare interventions. Ms. Kranz serves on the steering committees for the North Carolina Biotech Health Innovation Summit, RevTech Labs Venture Capital Health Tech Conference, the Medical Device Innovation Consortium’s XR in Healthcare, and as an advisor the U.S. Food and Drug Administration (FDA) on adoption of immersive technology as a digital therapeutic tool.

Headshot photograph of Paula Kranz

Mental Health Research Advisor

Dr. Hannah Pazderka

Dr. Pazderka has a long background of working in clinical research and project management within the field of psychiatry for over 20 years. Dr. Pazderka has been involved in multiple studies and project management of a variety of mental health initiatives. Dr. Hannah Pazderka received her PhD in Neuroscience from the University of Alberta in 2004, looking at indices of drug and alcohol craving. Since then, she has worked in a number of roles, including creation of public policy, research, and advocacy. Her primary research interests are in the regulation of impulsive and risk taking behaviour via the frontal lobes and subcortical reward structures. She has worked with a  number of different methodologies, including structural equation modeling, electrophysiology (ERPs and skin conductance), neuropsychological assessment, and epidemiology.

Mycology Advisors

Robert Rogers

Mr. Rogers has built, over five decades, a renowned international reputation for the education and promotion of medical mushrooms. Mr. Rogers has been a ethnomycologist and clinical herbalist for nearly 50 years and is presently a Clinical Professor in family medicine at the University of Alberta, and Adjunct Professor in graduate studies at York University. Mr. Rogers has published over 50 books on plant and mushroom medicine, including ‘The Fungal Pharmacy: The Complete Guide to Medicinal Mushrooms and Lichens of North America’; and in 2020 he published ‘Medicinal Mushrooms: The Human Clinical Trials’. Over the past 30 years, Mr. Rogers has taught plant and mushroom medicine at various post-secondary institutions and has formulated many mushroom-based supplements in the natural health products industry. Mr. Rogers previously chaired the Alberta Natural Health Agricultural Network, and Capital Health Community Health Council, and served on the editorial board of the International Journal of Medicinal Mushrooms.

Headshot photograph of Robert Rogers

Tradd Cotter

Mr. Cotter is a microbiologist and professional mycologist. Mr. Cotter specializes in organic horticulture, tissue culturing, and has more than 22 years experience cultivating and studying native fungi to the Southeast United States. Mr. Cotter lectures throughout North America, focusing his efforts on perpetual methods of mushroom cultivation. Mr. Cotter has undertaken numerous studies to explore applications for mushrooms in various industries and currently maintains over 200 species of fungi for food production and mycoremediation of environmental pollutants. Mr. Cotter has been the focus of interviews and documentaries in various media, including National Geographic. Mr. Cotter is the Designer and Chief Instructor of the North American Wild Mushroom Safety Certification Program and is a key contact for the North American Mycological Association Emergency Mushroom Toxicology group.

Headshot photograph of Tradd Cotter